Long-time healthcare investor looks to double number of life sciences startups in its 'evergreen' fund
Having consistently kept about a dozen life sciences companies in its portfolio over the past few decades, European investor Gimv is ready to double down — quite literally.
The Brussels-based firm is adding life sciences as a fifth platform, alongside consumer, healthcare, smart industry and sustainable cities, with the goal of growing the number of backed companies to 20.
Because Gimv is a listed company on its own and runs on an evergreen structure, it’s hard to pin down an exact figure, as with other VCs operating closed end funds, said Bram Vanparys, who’s newly appointed managing partner, head of life sciences.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.